A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
Authors:
Open Access
- 3 July 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1695
Abstract
Background: The early detection of type 1 diabetes (T1D) through screening for major islet autoantibodies is receiving increasing attention as a public health strategy, exemplified by the recent implementation of a pilot pediatric screening program in Italy. The transition from research-based screening to large-scale population initiatives needs automated and standardized assays that are capable of processing extensive sample volumes. Hence, this study aimed to evaluate the analytical performance and comparability of a fully automated chemiluminescence immunoassay (CLIA) compared to a conventional enzyme-linked immunosorbent assay (ELISA) for the detection of three classes of major islet antibodies—anti-GAD (GADA), anti-IA-2 (IA-2A), and anti-ZnT8 (ZnT8A). Methods: A total of 104 serum specimens were analyzed for each autoantibody using both ELISA (RSR and Medyzim, DYNES, DSX) and CLIA (MAGLUMI 800). Assay precision and linearity were assessed through intra-assay variability studies and dilution protocols. Methods agreement was evaluated with Passing–Bablok regression, Spearman’s correlation, Bland–Altman analysis, and Cohen’s kappa statistics. Results: The CLIA showed good precision and excellent linearity across clinically relevant concentration ranges of all islet antibodies. Correlation coefficients and categorical agreement between CLIA and ELISA were high (r > 0.96 and Cohen’s kappa >0.8 for all), with ZnT8A exhibiting the highest concordance. However, proportional biases were found, as CLIA systematically underestimated GADA and ZnT8A levels, while overestimated IA-2A compared to the ELISA. Conclusions: The CLIA displayed satisfactory precision and agreement with ELISA for GADA, IA-2A, and ZnT8A detection. Our findings support the use of these automated immunoassays in large-scale population initiatives for diagnosing T1D, but we also highlight the need for further efforts to achieve better inter-assay harmonization.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of ItalyDiabetes, Obesity and Metabolism, 2024
- Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshopsDiabetologia, 2023
- Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple CountEndocrine Reviews, 2021
- Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individualsScience Translational Medicine, 2021
- Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continentsDiabetologia, 2020
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesNew England Journal of Medicine, 2019
- Chemiluminescent immunoassay technology: what does it change in autoantibody detection?Autoimmunity Highlights, 2017
- The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY studyDiabetologia, 2015
- ELISA in the multiplex era: Potentials and pitfallsProteomics – Clinical Applications, 2015
- Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in ChildrenJAMA, 2013